Literature DB >> 11705847

Thalidomide and its analogues inhibit lipopolysaccharide-mediated Iinduction of cyclooxygenase-2.

J Fujita1, J R Mestre, J B Zeldis, K Subbaramaiah, A J Dannenberg.   

Abstract

We investigated the effect of thalidomide, a compound with immunomodulatory and antiangiogenic properties, on lipopolysaccharide (LPS)-mediated induction of cyclooxygenase-2 (Cox-2) and prostaglandin (PG) biosynthesis in murine macrophages. Thalidomide caused a dose-dependent inhibition of LPS-mediated induction of PGE(2) synthesis in RAW 264.7 cells. The induction of Cox-2 protein and mRNA by LPS was also suppressed by thalidomide. Based on the results of nuclear run-off assays and transient transfections, treatment with LPS stimulated Cox-2 transcription, an effect that was unaffected by thalidomide. Thalidomide decreased the stability of Cox-2 mRNA. A series of structural analogues of thalidomide also inhibited LPS-mediated induction of Cox-2 and PGE(2) synthesis. Taken together, these data provide new insights into the antineoplastic and anti-inflammatory properties of thalidomide.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11705847

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  17 in total

1.  Expression of COX-2 in platelet-monocyte interactions occurs via combinatorial regulation involving adhesion and cytokine signaling.

Authors:  Dan A Dixon; Neal D Tolley; Kristi Bemis-Standoli; Mark L Martinez; Andrew S Weyrich; Jason D Morrow; Stephen M Prescott; Guy A Zimmerman
Journal:  J Clin Invest       Date:  2006-09-21       Impact factor: 14.808

2.  Pomalidomide is nonteratogenic in chicken and zebrafish embryos and nonneurotoxic in vitro.

Authors:  Chris Mahony; Lynda Erskine; Jennifer Niven; Nigel H Greig; William Douglas Figg; Neil Vargesson
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-15       Impact factor: 11.205

3.  Transport of thalidomide by the human intestinal caco-2 monolayers.

Authors:  Shufeng Zhou; Yan Li; Phillip Kestell; Peter Schafer; Eli Chan; James W Paxton
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2005 Jan-Jun       Impact factor: 2.441

Review 4.  Current Trends of Renal Impairment in Multiple Myeloma.

Authors:  Punit Yadav; Mark Cook; Paul Cockwell
Journal:  Kidney Dis (Basel)       Date:  2016-02-03

Review 5.  Thrombotic complications in multiple myeloma: a report of three cases and review of the literature.

Authors:  Yonal Ipek; Hindilerden Fehmi; Besisik-Kalayoglu Sevgi; Sargin Deniz
Journal:  J Thromb Thrombolysis       Date:  2012-02       Impact factor: 2.300

6.  Immunomodulatory drug CC-4047 is a cell-type and stimulus-selective transcriptional inhibitor of cyclooxygenase 2.

Authors:  Gregory D Ferguson; Kristen Jensen-Pergakes; Candice Wilkey; Urvi Jhaveri; Normand Richard; Dominique Verhelle; Laure Moutouh De Parseval; Laura G Corral; Weilin Xie; Christopher L Morris; Helen Brady; Kyle Chan
Journal:  J Clin Immunol       Date:  2007-02-17       Impact factor: 8.317

7.  Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial.

Authors:  J N Gordon; T M Trebble; R D Ellis; H D Duncan; T Johns; P M Goggin
Journal:  Gut       Date:  2005-04       Impact factor: 23.059

Review 8.  Current status of thalidomide and CC-5013 in the treatment of metastatic prostate cancer.

Authors:  Tristan M Sissung; Silja Thordardottir; Erin R Gardner; William D Figg
Journal:  Anticancer Agents Med Chem       Date:  2009-12       Impact factor: 2.505

9.  Thalidomide inhibits inflammatory and angiogenic activation of human intestinal microvascular endothelial cells (HIMEC).

Authors:  Parvaneh Rafiee; Daniel J Stein; Victoria M Nelson; Mary F Otterson; Reza Shaker; David G Binion
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-11-19       Impact factor: 4.052

10.  Effects of a novel proteasome inhibitor BU-32 on multiple myeloma cells.

Authors:  Sudipa S Roy; Nameer B Kirma; Bindu Santhamma; Rajeshwar R Tekmal; Joseph K Agyin
Journal:  Cancer Chemother Pharmacol       Date:  2014-04-12       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.